Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy
Creators
- 1. Institute of Pharmacy and Biochemistry, Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, Staudingerweg 5, D-55128 Mainz (Germany)
- 2. Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Fritz-Strassmann Weg 6, D-55128 Mainz (Germany)
- 3. AIT Austrian Institute of Technology, Health & Environment Department, Biomedical Systems, Donau-City-Strasse 1/2, A-1220 Vienna (Austria)
Description
Neutron capture therapy for glioblastoma has focused mainly on the use of 10B as neutron capture isotope. However, 157Gd offers several advantages over boron, such as higher cross section for thermal neutrons and the possibility to perform magnetic resonance imaging during neutron irradiation, thereby combining therapy and diagnostics. We have developed different liposomal formulations of gadolinium-DTPA (Magnevist®) for application in neutron capture therapy of glioblastoma. The formulations were characterized physicochemically and tested in vitro in a glioma cell model for their effectiveness. Liposomes entrapping gadolinium-DTPA as neutron capture agent were manufactured via lipid/film-extrusion method and characterized with regard to size, entrapment efficiency and in vitro release. For neutron irradiation, F98 and LN229 glioma cells were incubated with the newly developed liposomes and subsequently irradiated at the thermal column of the TRIGA reactor in Mainz. The dose rate derived from neutron irradiation with 157Gd as neutron capturing agent was calculated via Monte Carlo simulations and set in relation to the respective cell survival. The liposomal Gd-DTPA reduced cell survival of F98 and LN229 cells significantly. Differences in liposomal composition of the formulations led to distinctly different outcome in cell survival. The amount of cellular Gd was not at all times proportional to cell survival, indicating that intracellular deposition of formulated Gd has a major influence on cell survival. The majority of the dose contribution arises from photon cross irradiation compared to a very small Gd-related dose. Liposomal gadolinium formulations represent a promising approach for neutron capture therapy of glioblastoma cells. The liposome composition determines the uptake and the survival of cells following radiation, presumably due to different uptake pathways of liposomes and intracellular deposition of gadolinium-DTPA. Due to the small range of the Auger and conversion electrons produced in 157Gd capture, the proximity of Gd-atoms to cellular DNA is a crucial factor for infliction of lethal damage. Furthermore, Gd-containing liposomes may be used as MRI contrast agents for diagnostic purposes and surveillance of tumor targeting, thus enabling a theranostic approach for tumor therapy
Availability note (English)
Available from http://dx.doi.org/10.1186/s13014-015-0342-7; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349485Additional details
Identifiers
Publishing Information
- Journal Title
- Radiation Oncology (Online)
- Journal Volume
- 10
- Journal Page Range
- vp.
- ISSN
- 1748-717X
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47069931
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- COMPUTERIZED SIMULATION; CONTRAST MEDIA; GADOLINIUM 157; GADOLINIUM COMPOUNDS; GLIOMAS; IN VITRO; IRRADIATION; LIPOSOMES; MONTE CARLO METHOD; NEUTRON CAPTURE THERAPY; NEUTRON REACTIONS; NMR IMAGING; THERMAL NEUTRONS; UPTAKE
- Descriptors DEC
- BARYON REACTIONS; BARYONS; CALCULATION METHODS; DIAGNOSTIC TECHNIQUES; DISEASES; ELEMENTARY PARTICLES; EVEN-ODD NUCLEI; FERMIONS; GADOLINIUM ISOTOPES; HADRON REACTIONS; HADRONS; INTERMEDIATE MASS NUCLEI; ISOTOPES; MEDICINE; NEOPLASMS; NERVOUS SYSTEM DISEASES; NEUTRON THERAPY; NEUTRONS; NUCLEAR MEDICINE; NUCLEAR REACTIONS; NUCLEI; NUCLEON REACTIONS; NUCLEONS; RADIOLOGY; RADIOTHERAPY; RARE EARTH COMPOUNDS; RARE EARTH NUCLEI; SIMULATION; STABLE ISOTOPES; THERAPY
Optional Information
- Copyright
- Copyright (c) Peters et al.
- Notes
- PMCID: PMC4349485; PMID: 25889824; PUBLISHER-ID: 342; OAI: oai:pubmedcentral.nih.gov:4349485; licensee BioMed Central. 2015